Journals / Solunum / 2016 / Cilt: 18 - Sayı: 1

Chronic Obstructive Pulmonary Disease Biomarkers

Journal
Solunum
Pages
3–10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we will review known candidate biomarkers for COPD, proposed pathways of pathogenesis, and future directions in the field.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Despite significant decreases in morbidity and mortality of cardiovascular diseases (CVD) and cancers, morbidity and cost associated with chronic obstructive pulmonary disease (COPD) continue to be increasing.
📊
Key Findings & Data:A more accurate phenotyping and the ability to assess the therapeutic response to new interventions and pharmaceutical agents may improve the statistical power of longitudinal clinical studies.
💡
Conclusion & Impact:In this study, we will review known candidate biomarkers for COPD, proposed pathways of pathogenesis, and future directions in the field.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Despite significant decreases in morbidity and mortality of cardiovascular diseases (CVD) and cancers, morbidity and cost associated with chronic obstructive pulmonary disease (COPD) continue to be increasing. Failure to improve disease outcomes has been related to the paucity of interventions improving survival. Insidious onset and slow progression halter research successes in developing disease-modifying therapies. In part, the difficulty in finding new therapies is because of the extreme heterogeneity within recognized COPD phenotypes. Novel biomarkers are necessary to help understand the natural history and pathogenesis of the different COPD subtypes. A more accurate phenotyping and the ability to assess the therapeutic response to new interventions and pharmaceutical agents may improve the statistical power of longitudinal clinical studies. In this study, we will review known candidate biomarkers for COPD, proposed pathways of pathogenesis, and future directions in the field.

🔖

Cite This Article

BEİKO, T., STRANGE, C. (2016). Chronic Obstructive Pulmonary Disease Biomarkers. Solunum, Cilt: 18 - Sayı: 1, 3–10. https://ajindex.com/articles/314244

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Stockley RA. Biomarkers in COPD: time for a deep breath. Thorax 2007
  2. [CrossRef] Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995
  3. 107 (5 Suppl): 187S-93S. [CrossRef] Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013
  4. [CrossRef] Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001
  5. [CrossRef] Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006
  6. [CrossRef] Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: expla- nation and elaboration. Ann Intern Med 2003
  7. W1-12. [CrossRef] Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010
  8. Gelb AF, Yamamoto A, Verbeken EK, Nadel JA. Unraveling the Pathophy- siology of the Asthma COPD Overlap Syndrome: Unsuspected mild cent- rilobular emphysema is responsible for loss of lung elastic recoil in never smoked asthmatics with persistent expiratory airflow limitation. Chest 2015
  9. [CrossRef] Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Res- pir Crit Care Med 2010
  10. [CrossRef] Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outco- mes in COPD: a novel phenotype. PloS One 2012
  11. e37483. [CrossRef] Sin DD, Man SF. Why are patients with chronic obstructive pulmonary di- sease at increased risk of cardiovascular diseases? The potential role of sys- temic inflammation in chronic obstructive pulmonary disease. Circulation 2003
  12. [CrossRef] Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009
  13. [CrossRef] Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, et al. The ef- fects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care